Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
COMMENT
Patrice P Cacoub
No abstract text is available yet for this article.
June 28, 2014: Lancet
#2
LETTER
Hubert Barennes, Merlin L Willcox, Bertrand Graz, Eric Pussard
No abstract text is available yet for this article.
April 5, 2014: Lancet
#3
LETTER
Mir Sadat-Ali, Haifa A Al-Turki
No abstract text is available yet for this article.
April 12, 2014: Lancet
#4
JOURNAL ARTICLE
Mazda Adli, Ulrich Hegerl
No abstract text is available yet for this article.
April 19, 2014: Lancet
#5
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 29, 2014: Circulation
#6
JOURNAL ARTICLE
Eve A Kerr, Timothy P Hofer
No abstract text is available yet for this article.
December 10, 2012: Archives of Internal Medicine
#7
JOURNAL ARTICLE
Marielle Beerepoot, Gerben Ter Riet, Suzanne E Geerlings
No abstract text is available yet for this article.
November 26, 2012: Archives of Internal Medicine
#8
JOURNAL ARTICLE
Chih-Cheng Chang, Hsiao-Chi Chuang, Cheng-Li Lin, Fung-Chang Sung, Yen-Jung Chang, Chung Y Hsu, Ling-Ling Chiang
OBJECTIVE: Patients with sleep apnea syndrome (SAS) carry a higher stroke risk. The differential stroke risk between sex and among different age groups has not yet been specifically addressed in previous studies. METHODS: Using a universal insurance claims database, we identified a large cohort of SAS patients from 1997 to 2010 and assessed the sex- and age-specific stroke risk compared with a control cohort matched for age, sex, and index date. Cox regression analyses were performed to assess the hazard ratio (HR) of stroke and the corresponding 95% confidence interval (CI)...
April 2014: Sleep Medicine
#9
REVIEW
Andrew Davenport, Jawad Ahmad, Ali Al-Khafaji, John A Kellum, Yuri S Genyk, Mitra K Nadim
Hepatorenal syndrome (HRS) is defined as the occurrence of renal dysfunction in a patient with end-stage liver cirrhosis in the absence of another identifiable cause of renal failure. The prognosis of HRS remains poor, with a median survival without liver transplantation of <6 months. However, understanding the pathogenesis of HRS has led to the introduction of treatments designed to increase renal perfusion and mean arterial blood pressure using vasopressors and albumin, which has led to improvement in renal function in ∼50% of patients...
January 2012: Nephrology, Dialysis, Transplantation
#10
RANDOMIZED CONTROLLED TRIAL
Daniel De Backer, Patrick Biston, Jacques Devriendt, Christian Madl, Didier Chochrad, Cesar Aldecoa, Alexandre Brasseur, Pierre Defrance, Philippe Gottignies, Jean-Louis Vincent
BACKGROUND: Both dopamine and norepinephrine are recommended as first-line vasopressor agents in the treatment of shock. There is a continuing controversy about whether one agent is superior to the other. METHODS: In this multicenter, randomized trial, we assigned patients with shock to receive either dopamine or norepinephrine as first-line vasopressor therapy to restore and maintain blood pressure. When blood pressure could not be maintained with a dose of 20 microg per kilogram of body weight per minute for dopamine or a dose of 0...
March 4, 2010: New England Journal of Medicine
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
